This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

This from the Prostate Cancer Charity site,

I know that some will already have seen this as it is included in a different thread. I am after as many signatures as I can generate so have started up a new topic just for this. Thanks to those who have already signed by the way.

If any one wants to sign the petition re testing it has been accepted on the Downing Street website and can be found at

http://petitions.pm.gov.uk/psa-testing/

It reads as follows


We the undersigned petition the Prime Minister to begin regular
testing for prostate cancer in men between the ages of 40 and
70

Prostate cancer is the largest cause of male deaths. A blood
test, known as PSA, can indicate that there is a problem that
needs investigating. In the Tryol district of Austria this is
being done and the mortality rates have fallen. Too many men
are being diagnosed only when it is too late for treatment to
be more than palliative.

The cancer technology of SR Pharma (SPA) is far more superior imo.

On the steep slope now...down 11p now.

Medical Marketing Int'l Group PLC
16 March 2007


Medical Marketing International Group plc

Notification of Major Interests in Shares


March 16th 2007. Medical Marketing International Group plc (the 'Company') (AIM:
MMG) the pharmaceutical company focused on the development of drugs for cancer
and infectious diseases, received notification on 15 March 2007 that as at
14 March 2007 Man Financial Limited was interested in 2,659,200 ordinary shares
of 0.2p each of the Company; this represents 4.53% of the Company's issued
share capital of 58,637,671 ordinary shares.

-ends-

Man financial.

Wonder if they have got wind of something.

Interesting.

Probably bought by Man for their spreadbetting side of the business.

No wonder the price was kicked down.

Got this from the other place, interesting.

The Real Capitalcity - 16 Mar'07 - 07:57 - 8241 of 8242


According to todays RNS, It looks like Man Financial SOLD 380,000 shares on the 14th?

A case of getting bored waiting?

I know I am! (but still holding on for now)

TRC.

Medical Marketing Int'l Group PLC
28 March 2007

Medical Marketing International Group plc

Further US patent for MMI's ruthenium cancer therapy portfolio

28th March 2007. Medical Marketing International Group plc (MMI) (AIM:MMG) the
pharmaceutical company focused on the development of drugs for cancer and
infectious diseases, today announces that it has been notified by the US Patent
and Trademark Office of the allowance of claims that further protect its
ruthenium chemotherapy portfolio. The patent will be granted following payment
of standard fees.

The 'virtual library' of ruthenium compounds protected by patents, such as the
current patent grant, now covers an extensive range of arene and ligand
chemistries, theoretically trillions of compounds, which are being evaluated
in-silico as part of the second generation program. First generation compounds
are progressing through pre-clinical testing programmes and are on track to
enable a clinical trial application (CTA) to be made in H2 2007.

David Best, Chairman of MMI Group, said 'Cytotoxics remain the mainstay of
cancer therapy, with the market for these drugs expected to achieve sales of
$12.8 billion by 2009. The further strengthening of the patent protection for
our vast ruthenium portfolio is particularly welcome as we anticipate the
clinical phase of development'.

-ends-
Contacts
Medical Marketing International Group plc Mark Burton
David Best Chief Technical Officer
Executive Chairman
Tel: +44 (0) 1223 477 677

Glad I held on to mine GF it's starting to look good. Thinking about topping up.

MS

Mickey I think we will have a good year end say around October onwards.

Sounds good to me GF. Our patience will be rewarded.

MS

agree, look at the chart, it is for sure the right moment to buy!!! I will sell other stocks even in loss and buy next week!

Malaga conference not far away now any one here attending..

Not me.

Theres too many distractions in Malaga........ hick.

Hope your doing well Mitzy.

MMGs time will come latter end of this year I believe.

Freebie from Mike Walters site....

Good News On The Way
30/3/2007 (119264)

Good News On The Way


How strange. Medical Marketing International (MMG) signals good progress towards a blockbuster DNA vaccine, and the shares actually ease 0.5p to 141p. Is everyone asleep?

Maybe the message was not simple enough. Or perhaps everyone who follows MMI knew about it anyway. Certainly it has been delivered in oblique fashion, just a short announcement drawing attention to the DNA Vaccines 2007 Conference in Malaga from May 23 to 25.

Professor Freda Stevenson of the University of Southampton will be speaking on May 23, with a presentation entitled DNA fusion gene vaccines: evolution and evaluation.

Professor Stevenson is leading the team which has made the breakthrough which appears to have made DNA vaccines a potent weapon for attacking cancer. That team is at the heart of MMIs Genvax subsidiary, and is working through clinical trials tackling a variety of cancers, supported by Cancer Research UK.

The charity funds the trials and effectively controls the release of the results. Professor Stevenson first presented results of the breakthrough at a major DNA Vaccine conference on March 18, 2005, and the stock market did not notice. Four days later, the company reported the results. After dipping below 170p, the shares began to respond, rising to 235p on the next day, and touching 300p a few days later as the full implications began to be understood. They later slumped under the weight of a malicious and ill-informed bear raid, have struggled to sustain a real recovery, and even now languish at 141p.

It appears, however, that we are about to see the next episode, and it could be exciting. While no-one knows what Professor Stevenson will say, it looks as if she will be able to release some data on the clinical trials. This will also be released to shareholders at the same time.

On May 24, Professor Stevenson will be moderator at a session which will include a presentation called DNA fusion vaccine delivery by intramuscular injection and electroporation - a well tolerated strategy for prostate cancer. This will be delivered by Dr Christian Ottensmeier, one of Professor Stevensons colleagues at Southampton, and by Dr Iacob Mathiesen, from Inovio of San Diego. Inovio is a leader in delivering genes and DNA vaccines by the electroporation process, which links injections with electric currents.

The title of this presentation clearly illustrates that the prostate cancer trials are going well, and are safe. Safety is a crucial hurdle in drug development.

It is fair to assume, then, that the May conference will bring news of important progress in the DNA vaccine trials for tackling prostate cancer, and that the results are looking good. There would be no point in presenting poor results, and while MMI is inhibited in releasing results of trials before they are complete, it would be duty bound to tell shareholders of any significant setback.

Though we will have to wait until late May for the full story, MMI is effectively indicating that it is well on the way towards establishing a DNA vaccine which can treat prostate cancer at an early stage, with a vaccine which is safe.

That is potentially very big news. We know that some DNA vaccines have to be tailored to each individual patient, opening a viable but less attractive market. The prostate cancer vaccine is generic one variety fits all and addresses a massive market. And if the vaccines succeed against prostate cancer, that adds credibility to other varieties being developed to tackle different cancers.

This underlines the potential of MMI. Currently capitalised at around 82m, it has the Genvax (51% owned but on the way to 58%) subsidiary with five phase two cancer vaccine trials in progress, ruthenium due to enter the clinic later this year, and a promising ribozyme project, all for spending of some 11m by the company.

There are discussions with virtually all of the leading pharmaceutical companies, and any one of these three areas could develop into a blockbuster - though any or all could fail, given the nature of this business.

It is frustrating that the share price is well below the level it reached two years ago, but the company has moved considerably further along in raising potential value. A high proportion of the shares is held by institutions who understand and believe in the story.

As ever, MMI looks an outstanding gamble. And as the significance of the May conference begins to filter through to the market, we could see useful action.

I have a holding in Medical Marketing.

Ends

Re assuring news out this morning...

Medical Marketing says trial using its DNA vaccine met all main goals
AFX


LONDON (Thomson Financial) - Medical Marketing International Group PLC said a clinical trial in follicular lymphoma using its DNA vaccine has met all its main goals.

The dose escalation phase I/II trial showed no significant safety concerns, and an immune response was seen in a number patients to both the immuno-stimulant component of the vaccine and their own cancer antigen, the company said.

'It is encouraging to see that in the first of these studies patients have demonstrated immune responses, indicating that by using DNA vaccines we can harness the body's natural defence mechanisms to fight against cancers,' Medical Marketing chairman David Best said in a statement.

TFN.newsdesk@thomson.com

faj/tc

Good post re MW GF.

MS

From the other side. Starting to look good.

Optimist at large - 19 Apr'07 - 07:16 - 8281 of 8289


Medical Mkting Int'l Data from Vaccine Trial
Date : 19/04/2007 @ 07:01
Source : UK Regulatory (RNS and others)

Free ADVFN Annual Company Report
Medical Mkting Int'l Data from Vaccine Trial


RNS Number:1319V
Medical Marketing Int'l Group PLC
19 April 2007

Medical Marketing International Group plc

MMI REPORTS POSITIVE DATA FROM FIRST DNA VACCINE TRIAL

--Provides update on ongoing DNA vaccine clinical trials programme--

April 19th 2007. Medical Marketing International Group plc (MMI) (AIM:MMG), the
pharmaceutical company focused on the development of drugs for cancer and
infectious diseases, announces that the Cancer Research UK-sponsored clinical
trial in Follicular Lymphoma, using the Company's DNA vaccine technology, has
met all its endpoints.

A 25-patient multi-centre dose escalation Phase I/II trial in Follicular
Lymphoma has been completed, meeting the following key endpoints:

* no significant safety concerns
* an immune response was observed in a number patients in validated assays
to both the immunostimulant component of the vaccine (Fragment C of tetanus
toxin) and patients' own cancer antigen

The full clinical and immunological data are being prepared for publication.

MMI also provides today the following update on other clinical studies currently
being undertaken with its DNA vaccines technology.

A 30-patient two-arm multi-centre fixed dose Phase I/II trial in CEA-expressing
cancers (cancers which express carcino-embryonic antigen, present in 70% of all
tumours) is underway in patients with and without metastatic disease. To date,
immunostimulant data is available in four patients and of these, three have
shown an immune response to the immunostimulant component of the vaccine (pDOM
epitope of tetanus toxin).

A 30-patient two-arm, two-centre dose escalation Phase I/II trial for prostate
cancer is also underway with and without electroporation as a delivery
mechanism:

* the first and second cohorts of ten patients have both now completed
recruitment
* the third and final dose cohort recruitment is underway, having
recruited four out of ten patients
* early immunological data for the immunostimulant component of the
vaccine (pDOM) are expected to be released Q2 2007


David Best, Chairman of MMI, said: "It is encouraging to see that in the first
of these studies patients have demonstrated immune responses, indicating that by
using DNA vaccines we can harness the body's natural defence mechanisms to fight
against cancers. We look forward to reporting the results of other DNA vaccine
trials currently underway in a range of indications".

Contacts

Medical Marketing International Group plc
David Best Mark Burton
Executive Chairman Chief Technical Officer
Tel: +44 (0) 1223 477677

About MMI Group

MMI is a pharmaceutical development company that identifies, acquires and
develops world-class compounds and technologies from leading academic
organizations. These technologies are aimed at producing blockbuster drugs to
satisfy unmet needs in major therapeutic markets. The company manages the
preclinical and early clinical development of drug candidates before pursuing
licensing partners to manage late-stage development. Through its three platform
technologies MMI has a risk-balanced portfolio of compounds in development for
the treatment of cancer and infectious disease. Please visit www.mmigroup.co.uk
for further information.

About Genvax

These vaccines are being developed through MMI's subsidiary, Genvax Limited.
Genvax has an exclusive world-wide licence from Cancer Research Technology to
technology for DNA vaccines that was developed at the University of Southampton.
Cancer Research UK is the sponsor of the Lymphoma and CEA cancer vaccine
clinical trials. Genvax has an option on further technology arising from this
programme. The clinical data arising from these trials vests in Cancer Research
Technology and Cancer Research UK, and are the subject of an arms length option
to Genvax under the terms of an agreement signed in 2005.

About Cancer Research Technology Limited
Cancer Research Technology Limited (CRT) is an oncology-focused development and
commercialisation company that realises cancer patient benefit from publicly-
funded research worldwide. CRT works closely with leading international cancer
scientists, their institutes and funding bodies to protect, develop and
commercialise oncology-related discoveries. CRT is wholly owned by Cancer
Research UK, the largest independent funder of cancer research in the world.
Further information about CRT can be found at www.CancerTechnology.com

About Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is to
beat cancer.

*Cancer Research UK carries out world-class research to improve
understanding of the disease and find out how to prevent, diagnose and treat
different kinds of cancer.
*Cancer Research UK ensures that its findings are used to improve the
lives of all cancer patients.
*Cancer Research UK helps people to understand cancer, the progress that
is being made and the choices each person can make.
*Cancer Research UK works in partnership with others to achieve the
greatest impact in the global fight against cancer.

For further information about Cancer Research UK's work or to find out how to
support the charity, please call 020 7009 8820 or visit our homepage:
www.cancerresearchuk.org

Again from the other side.

el magnifico - 19 Apr'07 - 10:06 - 8287 of 8289


bolador,

My take on today's RNS, for what it's worth:

The de-risking of MMG starts here. This process will continue on 23-25th May with more detailed news on the Ph I/II prostate trial and will take another step forward when ruthenium trials commence around mid-year. Viratis is a wild card.

I suspect that the footnote to the release, which points out that the clinical data reported today "vest" with CRUK and Cancer Research Technology, suggests that this release is timed for their purposes, rather than MMG's or Prof Stevenson's and so is a positive surprise for those of us who were expecting GenVax's prostate data to hit the tape first. As babysitter points out, that fun is still to come.

This release seems to tell us that some of the trials which started later have reached reportable stages earlier than the 2+year prostate trial. Clearly, these results are couched in modest terms :

"an immune response was observed in a number patients in validated assays to both the immunostimulant component of the vaccine"

but the point is that all the trials have delivered worthwhile outcomes and are all continuing.

Benny's point is well made, but if I read the recent seller correctly (see 100,000 shares at 8.11 am today crossing for 0.28p), it does not seem that he/she is sensitive to news, or they may have waited to see how the sp reacted. This is good, since it suggests that the supply of stock is from reasons other than the reasons we invest in MMG. This seller will eventually be taken out by patient investment buying, Benny may wake up to some real upside in the days ahead.

All IMHO

el